Naperville, IL -- (SBWIRE) -- 02/13/2014 -- Reportstack, provider of premium market research reports announces the addition of Mundipharma International Limited - Product Pipeline Review - 2014 market report to its offering
Mundipharma International Limited - Product Pipeline Review - 2014
Global Market Directs pharmaceuticals report, Mundipharma International Limited - Product Pipeline Review - 2014 provides data on the Mundipharma International Limiteds research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from proprietary databases, Mundipharma International Limiteds corporate website, SEC filings, investor presentations and featured press releases, both from Mundipharma International Limited and industry-specific third party sources, put together by team.
- Mundipharma International Limited - Brief Mundipharma International Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Mundipharma International Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Mundipharma International Limited with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Mundipharma International Limiteds pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Mundipharma International Limiteds strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Mundipharma International Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Mundipharma International Limiteds R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Mundipharma International Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Mundipharma International Limited and identify potential opportunities in those areas.
To view the table of contents for this market research report please visit